ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) Continues To Slip
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) the evolving bio tech firm attempting to develop new cures for various forms of human cancer had a forgettable start to 2014 at the markets yesterday. Its stock suffered a big sell out at the hands of investors leading to a 5.6 percent decrease in its market value in one day of trading. These sell out reversed the nearly 6.3 percent increase the stock had posted in its valuation during trading in the last week of December.
Stock Witnessed A See Saw
The sell-off in the stock of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) yesterday comes as a surprise to many of its long term investors since just on December 27, the drug firm had announced forward looking updates to its phase i clinical trials for its target cancer vaccine code named ICT-121 which is being positioned to treat recurring brain cancer.
Adding his commentary to the public announcement of the initiation of trails for this potential drug, ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) CEO Andrew Gengos has been quoted as saying, “The start of this ICT-121 trial signifies an expansion of our commitment to developing treatments for patients with GBM, and to the continued advancement of our pipeline of dendritic cell-based immunotherapeutic cancer vaccines. In 2014 we expect to have three active cancer vaccine clinical programs, led by ICT-107 in newly diagnosed GBM and including ICT-140 in ovarian cancer and ICT-121.”
About The Drug Maker
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is an $52.81 million market capped small cap drug maker which has its HQ in Calabasas. This firm has been classified as a clinical-stage biotechnology company. It has been engaged to in the design and development of treatments for various forms of cancer. It currently boasts of a big pipeline of target drugs which are in various phases of phase 11 clinical trials.